Meeting Announcement - Shanghai Lanwei Medical Laboratory Co., Ltd. will hold its 2024 Annual General Meeting on May 23, 2025, at 14:30 [1][2] - The meeting will combine on-site voting and online voting to facilitate shareholder participation [1][2] Voting Procedures - Shareholders can vote either in person or through a proxy with proper documentation [2][3] - Online voting will be available through the Shenzhen Stock Exchange trading system and internet voting system on May 23, 2025, from 9:15 to 15:00 [1][2] Agenda Items - The meeting will discuss proposals including the application for comprehensive credit limits and guarantees for 2025, and authorization for the board to issue shares through simplified procedures [3][5] - Proposal 11.00 requires a special resolution, needing over 2/3 of the valid votes, while other proposals require a simple majority [5] Registration Requirements - Natural person shareholders must present identification and proof of shareholding; corporate shareholders must provide additional documentation [5][6] - Remote shareholders can register via mail, ensuring their documents arrive by May 20, 2025 [5][6] Contact Information - For inquiries, shareholders can contact Yang Jingjing at the company's office in Shanghai [6]

Meeting Information - The 2024 Annual General Meeting (AGM) of Guangzhou Kingmed Diagnostics Group Co., Ltd. will be held on June 9, 2025, at 14:30 [2] - The meeting will be convened by the Board of Directors and will utilize a combination of on-site and online voting methods [2] - The on-site meeting will take place at the company's headquarters located at No. 10, Spiral Road, International Biological Island, Guangzhou [2] Voting Procedures - The online voting system will be the Shanghai Stock Exchange's shareholder meeting online voting system, available on June 9, 2025 [3][5] - Voting times for the trading system are from 9:15-9:25, 9:30-11:30, and 13:00-15:00 on the day of the meeting [3] - Shareholders can also vote via the internet voting platform from 9:15 to 15:00 on the same day [3] Meeting Agenda - The meeting will review several proposals, including the independent directors' annual performance report for 2024 [6] - Proposals 1-6 were approved in the Board of Directors and Supervisory Board meetings held on April 25, 2025 [6] - Proposals 7 and 8, related to the remuneration of directors and supervisors, will be submitted for voting with the directors and supervisors abstaining from voting [6] Attendance and Registration - Shareholders registered with the China Securities Depository and Clearing Corporation Limited Shanghai Branch after the market close on the registration date are eligible to attend [8] - Registration for natural persons requires identification and shareholder account card, while legal entities must provide additional documentation [11][12] - The registration period for on-site attendance is from June 6, 2025, 9:00 to 17:00 [12] Additional Services - To enhance participation, the company will use a reminder service to notify shareholders about the meeting and voting [7] - Shareholders with multiple accounts can aggregate their voting rights across all accounts [7][8]

Core Viewpoint - Zhang Hezi, once known as the "Nucleic Acid King," is now embroiled in legal disputes with health authorities over unpaid testing fees, highlighting the financial struggles faced by third-party medical testing companies in the post-pandemic landscape [1][11]. Group 1: Legal Disputes and Financial Challenges - Shenzhen Nucleic Acid Laboratory, under Zhang Hezi, has initiated lawsuits against various health departments for unpaid nucleic acid testing fees, indicating a significant issue with accounts receivable in the industry [1][2]. - The lawsuits primarily target health departments in smaller cities, revealing the complex payment issues within the third-party medical testing sector [1][2]. - A health department representative confirmed that the disputes are related to nucleic acid testing fees, which have been settled for relatively small amounts [1][2]. Group 2: Company Background and Growth - Zhang Hezi founded Shenzhen Nucleic Gene Technology Co., which controls Shenzhen Nucleic Acid Laboratory, and has been a major player in nucleic acid testing during the COVID-19 pandemic [1][5]. - The laboratory has been involved in testing across numerous cities, including Wuhan and Shenzhen, and claims to have conducted over 700 million tests during the pandemic [2][7]. - The rapid expansion of the laboratory was facilitated by a franchise model, attracting over 2,300 franchisees, and generating significant revenue during the peak of the pandemic [8]. Group 3: Regulatory Issues and Penalties - The laboratory has faced multiple penalties for issues such as falsifying test results and improper management of staff, indicating ongoing regulatory scrutiny [3][4]. - Specific incidents, such as the misreporting of test results in Lanzhou, have brought negative attention to the laboratory and its operations [3][4]. Group 4: Future Prospects and Business Direction - Following the decline in business post-pandemic, Zhang Hezi's companies are reportedly facing financial difficulties, with some being restricted from high consumption due to legal disputes [11]. - The company has attempted to diversify into real estate and pre-prepared food sectors, but the ongoing legal issues continue to overshadow its reputation [11]. - Despite ambitions for further expansion and IPO plans, the company has yet to achieve successful public listing due to stringent regulatory reviews [11].

Group 1 - The "Guangzhou Kingmed Diagnostics Group Co., Ltd." has successfully registered its "Targeted Sequencing Dataset for Respiratory Pathogen Microorganisms" as one of the top ten typical cases of data intellectual property registration [1] - The dataset analyzes the epidemic characteristics of specific respiratory pathogens, providing a basis for disease control evaluation and the formulation of refined prevention strategies [1] - The monitoring platform built on this dataset has significantly improved diagnostic capabilities, reducing the time for infectious disease alerts to 48 hours and increasing the detection rate in grassroots hospitals by over 28% [1] Group 2 - The health care industry is characterized as a data-intensive sector, with significant data scale, complexity, and application depth, playing a crucial role in precision medicine [2] - The Guangdong Provincial Market Supervision Administration is actively providing data intellectual property consulting services to health care enterprises, including in-depth research on Kingmed's data composition and potential value [2] - The successful registration of the dataset was facilitated by identifying core elements of technological innovation across the entire data collection and application chain [2]

Core Viewpoint - The company reported a significant decline in revenue and net profit for 2024, attributed to the impact of DRG implementation and industry restructuring [1] Group 1: Financial Performance - In 2024, the company achieved revenue of 7.19 billion, a year-on-year decrease of 15.81% [1] - The net profit attributable to shareholders was -0.38 billion, a year-on-year decline of 159.26% [1] - The fourth quarter of 2024 saw revenue of 1.57 billion, down 29.57% year-on-year, with a net profit of -0.48 billion, a staggering decline of 805.23% [1] - For Q1 2025, revenue was 1.47 billion, a decrease of 20.35% year-on-year, with a net profit of -0.03 billion, down 49.09% [1] Group 2: Cost Management and Efficiency - The company is focusing on quality improvement and efficiency enhancement, integrating AIoT technology to build cost advantages, resulting in a 21% year-on-year increase in laboratory productivity [2] - Logistics costs decreased by 7.29% due to optimized logistics routes [2] - The cost of reagents fell by 15.54% through integrated supply chain management [2] - The implementation of smart screening and automated testing workstations has increased efficiency by four times and saved nearly a hundred manpower costs [2] Group 3: Digital Transformation and Data Utilization - The company is advancing its "Medical Testing 4.0" vision, focusing on digital transformation in big data and AI [3] - A data platform managing over 23PB of medical data is being developed, with an annual growth rate of 1PB [3] - The company is leveraging its accumulated medical knowledge to train industry-specific AI models, enhancing service delivery through a platform with over 570,000 registered users [3] - Collaborations with data industry associations aim to promote a secure and efficient data space for better resource utilization [3] Group 4: Profitability Metrics - The overall gross margin for 2024 decreased by 3.33 percentage points to 33.15%, primarily due to weakened scale effects and price reductions [4] - The net profit margin fell by 13.23 percentage points to -5.77% [4] - In Q4 2024, the gross margin was 25.96%, with a net profit margin of -31.74% [4] Group 5: Future Projections - Revenue forecasts for 2025-2027 are 7.19 billion, 7.75 billion, and 8.60 billion, with year-on-year growth rates of 0%, 8%, and 11% respectively [5] - Projected net profits for the same period are 0.30 billion, 0.57 billion, and 0.81 billion, reflecting growth rates of 179%, 90%, and 41% [5] - The expected EPS for 2025 is 0.65, with a corresponding PE ratio of 47 based on the closing price on May 7, 2025 [5]

Core Viewpoint - The company reported a significant decline in revenue and net profit for 2024, primarily due to intensified industry competition and price reductions in medical testing services, but it is expected to recover profitability through operational optimization and AI-driven digital transformation [1][2][3]. Financial Performance - In 2024, the company achieved a revenue of 7.19 billion yuan, a year-over-year decrease of 15.81%, with a net loss attributable to shareholders of 381 million yuan, reflecting a year-over-year decline of 159.26% [1][2]. - The first quarter of 2025 saw a revenue of 1.47 billion yuan, down 20.35% year-over-year, with a net loss of 28 million yuan, a decrease of 49.09% year-over-year [1][2]. Operational Challenges - The decline in revenue was attributed to the implementation of medical reform, which led to lower testing service prices, and increased competition within the industry [2]. - The gross profit margin fell by 2.71 percentage points to 32.81%, exacerbated by a longer accounts receivable collection period and increased credit impairment losses of 619 million yuan in 2024 [2]. Strategic Initiatives - The company is enhancing operational efficiency by accelerating centralized procurement and production, resulting in a 15.54% decrease in reagent costs and a 21% improvement in laboratory productivity [2]. - The company is investing in AI and digital transformation, launching a medical testing model "Yujian Yiyan" and related applications to provide comprehensive testing services, with over 89,000 registered doctors [3]. Future Outlook - Revenue projections for 2025-2027 are estimated at 7.16 billion, 8.08 billion, and 9.23 billion yuan, with year-over-year growth rates of -0.5%, 13.0%, and 14.1% respectively [3]. - Expected net profit attributable to shareholders for the same period is forecasted to be 305 million, 740 million, and 923 million yuan, representing significant growth rates of 180.1%, 142.3%, and 24.8% respectively [3].

2025年4月25日，西安区域医学检验中心(以下简称"西安医检")与陕西中医药大学签署"产学研"合作协议，并为"陕西中医药大学医学技术学院实践教学基 地"揭牌。 其中，西安医检将成为陕西中医药大学医学技术学院实践教学基地，学院将选派优秀学生赴西安医检参加实践实习；西安医检将选派资深专家作为创新创 业导师，开设创新创业课程指导，从校、企两方面提升学生的创新思维和能力；西安医检还将定期指派专家赴学院开展学术讲座、创新创业论坛及行业前 沿科普等专题讲座或培训。 双方签署"产学研"合作协议，遵循国家科技工作"自主创新，重点跨越，支撑发展，引领未来"的指导方针，校企双方将本着优势互补、资源共享、互利互 惠、共同发展的基本原则，共同探讨建立长期、有效合作的校企合作新模式。 西安医检副总裁颜桦表示，西安区域医学检验中心致力于打造医学检验行业开放、共赢的平台，其中校企合作是重中之重，希望以签署"产学研"合作协议 和实践教学基地的成立为契机，将双方的技术、专家、师资和科研等优势深度结合，探索出医学检验领域校企合作的新方向，实现校企共赢，携手将检验 医学水平提升到新的高度。 西安区域医学检验中心 陕西中医药大学医学技术学院副书记 ...

证券代码：603882 证券简称：金域医学公告编号：2025-016 广州金域医学检验集团股份有限公司 二、董事会会议审议情况 广州金域医学检验集团股份有限公司董事会 出席本次会议的全体董事对本次会议的议案进行了认真审议，并以记名投票表决方式通过以下决议： （一）审议通过《广州金域医学检验集团股份有限公司市值管理制度》 经审议，为加强公司市值管理工作，进一步规范公司市值管理行为，维护公司、投资者及其他利益相关 者的合法权益，董事会同意公司依据《中华人民共和国公司法》、《中华人民共和国证券法》、《上海 证券交易所股票上市规则》、《上市公司监管指引第10号一一市值管理》及其他法律、法规及规范性文 件的规定，制定《广州金域医学检验集团股份有限公司市值管理制度》。 表决结果：9 票同意，占公司全体董事人数的100%，0票反对，0票弃权。 特此公告。 第四届董事会第五次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 广州金域医学检验集团股份有限公司（以下简称"公司"）第四届董事会第五次会议于2025 ...